Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy
International Journal of Molecular Sciences · 17.01.2026 · 27 (2) · 939
DOI: 10.3390/ijms27020939 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.01.2026. Verfasst von Adam P Jones und 4 weiteren Autor:innen. Beteiligte Einrichtung: Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Tumor Microenvironment, Ovarian Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIDCD NIH HHS, ACS.
Abstract (Originalsprache)
Ovarian cancer is one of the deadliest gynecological malignancies, where most patients become clinically symptomatic at advanced stages of disease due to the lack of effective diagnostic screening. Despite recent advances in surgical resection and chemotherapy, recurrent ovarian cancer remains largely refractory to treatment, resulting in poor prognosis. The ovarian cancer tumor microenvironment (TME) is highly abnormal and presents a significant barrier to successful therapy. A combination of abnormal vasculature, desmoplastic extracellular matrix, and aberrantly activated hypoxic and immune-suppressive pathways culminates in promoting tumor growth, dissemination, chemoresistance, and immunosuppression. Whilst immune checkpoint inhibitors have shown success in other cancers, their application in ovarian cancer, particularly at advanced stages, remains limited. In this review, we discussed the application of tumor extracellular matrix normalizing therapies in preclinical models of advanced ovarian cancer, and their synergistic benefit to chemotherapy and immunotherapy. Collectively, these insights underscore TME normalization as a promising therapeutic strategy with the potential to improve ovarian cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023, China.
- Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
- Gynecologic Cancers Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
ORCID-Profile: Bo R Rueda, Oladapo O Yeku
Förderung
- NINDS NIH HHS
- NIDCD NIH HHS
- ACS
- NIH
- Department of Defense New Investigator Award
- Investigator-Initiated Research Award
- Clinical Trial Award
- Children’s Tumor Foundation Drug Discovery Initiative
Zitieren
APA
Jones, A. P., Zhao, Y., Rueda, B. R., Yeku, O. O., & Xu, L. (2026). Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy. International Journal of Molecular Sciences, 27(2), 939. https://doi.org/10.3390/ijms27020939
Vancouver
Jones AP, Zhao Y, Rueda BR, Yeku OO, Xu L. Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy. International Journal of Molecular Sciences. 2026;27(2):939. doi:10.3390/ijms27020939
BibTeX
@article{Jones2026,
author = {Jones, Adam P and Zhao, Yanxia and Rueda, Bo R and Yeku, Oladapo O and Xu, Lei},
title = {Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {2},
pages = {939},
doi = {10.3390/ijms27020939}
}
EUVIMED